Cabometyx (Cabozantinib S-Malate) Patent Expiration, LOE Window & CMS Spending

Cabometyx (Cabozantinib S-Malate) by Exelixis: FDA Orange Book core substance LOE 2030-10-08 (last listed 2033-07-09), 1 AB generics, $1.35B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorExelixis
FDA Application & PathwayN208692 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-10-08
Last Listed Patent or Exclusivity Date2033-07-09
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.35B
2024 Medicare Part D Spend$1.22B
2024 Medicaid Spend$128.7M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 18.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.